Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Leonard Green & Partners.Click [here] to learn how to join our investigation and obtain additional information or contact us at [[email protected]] ...

therapeutic effects. Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the U.S. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology and oncology products from Europe and Asia to the U.S.With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., ...

Duke Energy Foundation commits $500,000 to support local environmental resilience programs across North Carolina [Accessibility Statement] Skip Navigation- Funding will support projects aimed at enhancing and preserving the state's natural surroundings- Up to 20 nonprofits will each receive a $25,000 grant – [apply] by March 13CHARLOTTE, N.C., Feb. 23, 2026 /PRNewswire/ -- Duke Energy Foundation is committing $500,000 to support local environmental resilience projects across North Carolina that conserve nat ...

thNORTHBROOK, Ill., Feb. 23, 2026 /PRNewswire/ -- The Allstate Corporation (NYSE: ALL) announced that Jess Merten, President, Property-Liability, will present at the Raymond James 47 Annual Institutional Investors Conference at 6:30 a.m. CT on Monday, March 2.  A webcast of the presentation can be accessed at www.allstateinvestors.com. A replay will also be posted there shortly after the presentation ends. Financial information, including material announcements about The Allstate Corporation, is routinely ...

AT&T Named America's Best and Fastest Internet [Accessibility Statement] Skip NavigationDALLAS, Feb. 23, 2026 /PRNewswire/ --Key Takeaways:- Nearly half of consumers are willing to switch for better, faster internet. These wins prove AT&T is the destination for what consumers want.- AT&T Fiber also has the fastest speeds in the U.S. for the fourth consecutive time.- AT&T Fiber wins Ookla®'s first-ever "Best Home Internet" in the U.S. award.What's the News: Today, AT&T Fiber received Ookla's first-ever Best ...

S&P Dow Jones Indices and Lincoln International Unveil New Benchmarks for the Private Loan Market with Launch of S&P Lincoln Senior Debt Indices [Accessibility Statement] Skip NavigationNEW YORK, Feb. 23, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI"), the world's leading index provider, in collaboration with Lincoln International, a global investment banking advisory firm, today announced the launch of the first two indices in the S&P Lincoln Senior Debt Index Series, to provide key benchmarking to ...

Greenberg Traurig Represents ARKO Petroleum Corp. in $200M Initial Public Offering [Accessibility Statement] Skip NavigationMIAMI, Feb. 23, 2026 /PRNewswire/ -- Global law firm [Greenberg Traurig, LLP] represented wholesale fuel distributor ARKO Petroleum Corp. (Nasdaq: APC), a subsidiary of ARKO Corp. (Nasdaq: ARKO), in connection with its $200 million initial public offering (IPO). The offering closed Feb. 13 and provided the company with net proceeds of approximately $183.2 million.The IPO consisted of 1 ...

Unisys Strengthens Device Subscription Service To Support Complex Edge Computing and IoT Deployments [Accessibility Statement] Skip NavigationCollaboration with Dell Technologies empowers organizations with smarter, more agile digital workplace solutionsBLUE BELL, Pa., Feb. 23, 2026 /PRNewswire/ -- [Unisys] (NYSE: UIS) is advancing its [Device Subscription Service](DSS), in collaboration with [Dell Technologies]. This strengthened alliance of more than 30 years delivers comprehensive and flexible solutions ...

Core Insights - The Gallagher AI Adoption and Risk Survey indicates that 82% of businesses report positive impacts from AI integration, with 63% having fully operationalized AI in their operations, a significant increase from 45% in 2025 [1][1][1] - A majority of respondents (83%) believe AI will drive future revenue growth, while 93% feel confident in their understanding of AI risks [1][1][1] AI Adoption and Implementation - 63% of businesses have fully implemented AI, focusing on IT operations, client-facing functions, and analytics, up from 45% in the previous year [1][1][1] - Nearly two-thirds (63%) of organizations are measuring ROI from AI, estimating an average of 28 months to realize returns [1][1][1] Challenges and Concerns - Key challenges include AI errors, misinformation, and hallucinations (57%), legal and reputational risks from AI misuse (56%), and data protection and privacy violations (55%) [1][1][1] - Over half of respondents report skills gaps and recruitment challenges related to AI [1][1][1] Ethical Considerations and Human Element - 46% of organizations have appointed an AI ethics officer to address ethical considerations in AI deployment [1][1][1] - The importance of maintaining a human element in AI technology, including personal accountability, governance, and training, is emphasized [1][1][1] Customer Experience Focus - The survey highlights the need to prioritize customer experience in AI adoption, as stated by Gallagher's Global Chief Digital Officer [1][1][1] - Gallagher's ongoing investment in data, analytics, and workforce skill development aims to enhance client outcomes in a rapidly evolving landscape [1][1][1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting information regarding its drug AMT-130 during a specific class period, leading to significant stock price decline [1]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [1]. Legal Allegations - The lawsuit claims that uniQure misrepresented the FDA approval status of its Pivotal Study for AMT-130 and downplayed the potential delay in its Biologics License Application (BLA) timeline [1]. - The complaint highlights that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission, causing uncertainty regarding the submission timeline [1]. Stock Performance Impact - Following the disclosure on November 3, 2025, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share the next trading day [1].